Left Atrial Appendage Closure in Atrial Fibrillation Patients with Cancer
Authors:
- David ZweikerDavid Zweiker
- Jutta Bergler-KleinJBJutta Bergler-Klein
- Lukas FiedlerLFLukas Fiedler
- Gabor G. TothGabor G. Toth
- Reinhard AchleitnerRAReinhard Achleitner
- Alexandra SchratterASAlexandra Schratter
- Guenter StixGSGuenter Stix
- Harald GabrielHGHarald Gabriel
- Ronald K. BinderRBRonald K. Binder
- Martin RammerMRMartin Rammer
- Michael PfefferMPMichael Pfeffer
- Paul VockPVPaul Vock
Open Access
- 30 October 2024
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (21) , 6514
Abstract
Background: There are limited data about left atrial appendage closure (LAAC) in patients with cancer. We therefore sought to compare the outcome after LAAC in patients with vs. without cancer in a multicentre registry. Methods: In this sub-analysis of the prospective Austrian LAAC Registry, we analysed consecutive patients undergoing LAAC to assess the relationship between baseline characteristics and outcome in patients with vs. without cancer. Inverse probability weighting was performed to adjust for differences in baseline characteristics. Results: A total of 486 consecutive patients from 9 centres with a median age of 75 years (IQR 70–79 years; 35.8% female) were included. Fifty-seven patients (11.7%) had a history of cancer. The median CHA2DS2-VASc and HAS-BLED scores were similar in both groups (median [IQR], 4 [4–6] vs. 5 [3–5], p = 0.415; 4 [3–4] vs. 3 [3–4], p = 0.428 in cancer vs. other patients). Cancer patients were significantly older, and anaemia and gastrointestinal bleeding were significantly more common. Major procedural complications occurred in 5.3% vs. 7.0% (p = 0.276) of patients. The cumulative five-year survival rates were 80.7% and 84.8% in cancer vs. other patients (adjusted hazard ratio for death 1.29 [95% CI 0.67–2.48], p = 0.443). There were also no differences in one-year survival (96.1% vs. 94.0%, p = 0.582) and five-year event-free survival (64.9% vs. 74.4%, p = 0.124). Conclusions: In daily clinical practice, LAAC has already been accepted as a treatment option in patients with cancer. This retrospective analysis shows that short-term and adjusted long-term complications are similar in patients with vs. without cancer undergoing LAAC.Keywords
Funding Information
- Boston Scientific
This publication has 21 references indexed in Scilit:
- 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)European Heart Journal, 2024
- Outcomes of patients with cancer undergoing percutaneous left atrial appendage occlusionJournal of Interventional Cardiac Electrophysiology, 2023
- Left Atrial Appendage Closure Outcomes in Patients With Cancer at a Single Tertiary CenterThe American Journal of Cardiology, 2023
- Left Atrial Appendage Occlusion in Patients With Atrial Fibrillation and CancerJACC: Cardiooncology, 2023
- Arterial Thromboembolism in Patients With AF and CHA2DS2-VASc Score 0-2 With and Without CancerJACC: Cardiooncology, 2023
- 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)European Heart Journal, 2022
- Incidence, risk factors, and mortality of atrial fibrillation in breast cancer: a SEER-Medicare analysisEuropean Heart Journal, 2021
- Procedural and Short-Term Outcomes of Percutaneous Left Atrial Appendage Closure in Patients With CancerThe American Journal of Cardiology, 2021
- Risk of Malignant Cancer Among Women With New-Onset Atrial FibrillationJAMA Cardiology, 2016
- Age and Cancer RiskAmerican Journal of Preventive Medicine, 2014